Lancet Haematology

Papers
(The H4-Index of Lancet Haematology is 44. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Towards reparatory measures: blood donation, health systems, and men who have sex with men286
A new player in IDH1 mutated myeloid neoplasias212
Pegcetacoplan: climbing up the complement cascade173
Risk stratification for Down syndrome and acute lymphocytic leukaemia: one size does not fit all163
Low-dose aspirin versus placebo in postpartum venous thromboembolism: a multi-national, pilot, randomised, placebo-controlled trial147
Music therapy for children undergoing transplantation147
Lines of the haematology community125
Allogeneic haematopoietic stem-cell transplantation versus gene therapy for haemoglobinopathies119
Orla McCourt—making space for proactive rehabilitation in haematology113
Making blood count109
Further investment for cancer reduction in the USA106
The value of teaching the influence of sex and gender on health outcomes100
Mitapivat for treatment of pyruvate kinase deficiency97
Reducing toxic waste: improving toxicity capture in childhood cancer94
A+AVD versus eBEACOPP in advanced-stage Hodgkin lymphoma92
Have cancer, will travel86
Modelling the mortality of sickle cell disease in Africa78
Using immunogenetics to inform immunotherapy of lymphoid malignancies73
Brushes with Cancer goes digital73
A century between pandemics and poisonings72
Future role of topical pimecrolimus in early stage mycosis fungoides?71
Haploidentical bone marrow transplantation for severe aplastic anaemia: looking to the future69
Filling the data gaps on sickle cell anaemia in sub-Saharan Africa68
Retinopathy associated with severe thrombocytopenia68
Neutrophil-erythrocyte rosettes suggestive of Coombs-negative autoimmune haemolysis67
Oleksandr Lysytsia: the war in Ukraine has changed everything about our lives65
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study65
Haematology's role on the path to health for all Africans64
Consideration of ATG-free therapy with eltrombopag and cyclosporine for severe aplastic anaemia63
COVID-19 vaccination in haematology services63
Prioritising health equity alongside donation safety – Authors' reply61
Prehospital blood transfusion for haemorrhagic shock56
Prehospital blood transfusion for haemorrhagic shock55
Sex specific definitions of anaemia reflect androgen production – Authors' reply55
Lower strength stockings: is less better?52
Obiageli Nnodu: sickle cell disease in Africa's largest nation51
ISTH 2021 Congress51
PARP inhibitors—understanding the risk of myelodysplastic syndrome and acute myeloid leukaemia48
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial48
Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis48
Ultra-low-dose radiation for gastric MALT lymphoma48
Challenges in haemophilia care in the Philippines47
In the trenches47
Will the changing therapeutic landscape meet the needs of patients with sickle cell disease?46
Optimising maintenance therapy after transplantation: sorafenib's role in patients with FLT3-ITD acute myeloid leukaemia44
Retinal haemorrhage as a complication of blastic plasmacytoid dendritic cell neoplasm44
On the basis of sex: outcomes in myelodysplastic syndromes44
0.12007713317871